Cargando…
Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial
The emergence of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an unprecedented threat for the human population, necessitating rapid and effective intervention measures. Given the main infection route by airborne transmission, significant attention has been bestowed upo...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057949/ https://www.ncbi.nlm.nih.gov/pubmed/35504446 http://dx.doi.org/10.1016/j.virusres.2022.198791 |
_version_ | 1784698014753882112 |
---|---|
author | Meister, Toni Luise Gottsauner, Josef-Maximilian Schmidt, Barbara Heinen, Natalie Todt, Daniel Audebert, Franz Buder, Felix Lang, Henriette Gessner, André Steinmann, Eike Vielsmeier, Veronika Pfaender, Stephanie Cieplik, Fabian |
author_facet | Meister, Toni Luise Gottsauner, Josef-Maximilian Schmidt, Barbara Heinen, Natalie Todt, Daniel Audebert, Franz Buder, Felix Lang, Henriette Gessner, André Steinmann, Eike Vielsmeier, Veronika Pfaender, Stephanie Cieplik, Fabian |
author_sort | Meister, Toni Luise |
collection | PubMed |
description | The emergence of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an unprecedented threat for the human population, necessitating rapid and effective intervention measures. Given the main infection route by airborne transmission, significant attention has been bestowed upon the use of antiseptic mouthrinses as a way to possibly reduce infectious viral titers. However, clinical evaluations are still sparse. Thus, we evaluated a wide variety of antiseptic agents that can be used as mouthrinses for their antiviral effects in vitro and their respective mode of action. One of the most promising antiseptic agents (benzalkoniumchloride, BAC) was used in a randomized placebo-controlled clinical trial with subsequent analysis of viral loads by RT-qPCR and virus rescue in cell culture. Mechanistic analysis revealed that treatment with BAC and other antiseptic agents efficiently inactivated SARS-CoV-2 in vitro by primarily disrupting the viral envelope, without affecting viral RNA integrity. However, the clinical application only resulted in a mild reduction of viral loads in the oral cavity. These results indicate that gargling with mouthrinses comprising single antiseptic agents may play a minor role towards a potential reduction of transmission rates and thus, these findings are of utmost importance when considering alternative COVID-19 prevention strategies. |
format | Online Article Text |
id | pubmed-9057949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90579492022-05-02 Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial Meister, Toni Luise Gottsauner, Josef-Maximilian Schmidt, Barbara Heinen, Natalie Todt, Daniel Audebert, Franz Buder, Felix Lang, Henriette Gessner, André Steinmann, Eike Vielsmeier, Veronika Pfaender, Stephanie Cieplik, Fabian Virus Res Article The emergence of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an unprecedented threat for the human population, necessitating rapid and effective intervention measures. Given the main infection route by airborne transmission, significant attention has been bestowed upon the use of antiseptic mouthrinses as a way to possibly reduce infectious viral titers. However, clinical evaluations are still sparse. Thus, we evaluated a wide variety of antiseptic agents that can be used as mouthrinses for their antiviral effects in vitro and their respective mode of action. One of the most promising antiseptic agents (benzalkoniumchloride, BAC) was used in a randomized placebo-controlled clinical trial with subsequent analysis of viral loads by RT-qPCR and virus rescue in cell culture. Mechanistic analysis revealed that treatment with BAC and other antiseptic agents efficiently inactivated SARS-CoV-2 in vitro by primarily disrupting the viral envelope, without affecting viral RNA integrity. However, the clinical application only resulted in a mild reduction of viral loads in the oral cavity. These results indicate that gargling with mouthrinses comprising single antiseptic agents may play a minor role towards a potential reduction of transmission rates and thus, these findings are of utmost importance when considering alternative COVID-19 prevention strategies. The Author(s). Published by Elsevier B.V. 2022-07-15 2022-05-02 /pmc/articles/PMC9057949/ /pubmed/35504446 http://dx.doi.org/10.1016/j.virusres.2022.198791 Text en © 2022 The Author(s). Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Meister, Toni Luise Gottsauner, Josef-Maximilian Schmidt, Barbara Heinen, Natalie Todt, Daniel Audebert, Franz Buder, Felix Lang, Henriette Gessner, André Steinmann, Eike Vielsmeier, Veronika Pfaender, Stephanie Cieplik, Fabian Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial |
title | Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial |
title_full | Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial |
title_fullStr | Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial |
title_full_unstemmed | Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial |
title_short | Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial |
title_sort | mouthrinses against sars-cov-2 – high antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057949/ https://www.ncbi.nlm.nih.gov/pubmed/35504446 http://dx.doi.org/10.1016/j.virusres.2022.198791 |
work_keys_str_mv | AT meistertoniluise mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial AT gottsaunerjosefmaximilian mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial AT schmidtbarbara mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial AT heinennatalie mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial AT todtdaniel mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial AT audebertfranz mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial AT buderfelix mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial AT langhenriette mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial AT gessnerandre mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial AT steinmanneike mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial AT vielsmeierveronika mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial AT pfaenderstephanie mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial AT cieplikfabian mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial |